Erasca, Inc. (ERAS)
| Market Cap | 6.65B +1,566.0% |
| Revenue (ttm) | n/a |
| Net Income | -277.02M |
| EPS | -0.96 |
| Shares Out | 347.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,704,606 |
| Open | 18.96 |
| Previous Close | 19.02 |
| Day's Range | 18.13 - 19.85 |
| 52-Week Range | 1.33 - 24.28 |
| Beta | 0.66 |
| Analysts | Buy |
| Price Target | 21.20 (+10.59%) |
| Earnings Date | Aug 11, 2026 |
About ERAS
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ERAS stock is "Buy." The 12-month stock price target is $21.2, which is an increase of 10.59% from the latest price.
News
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...
Erasca price target raised to $24 from $21 at Jefferies
Jefferies raised the firm’s price target on Erasca (ERAS) to $24 from $21 and keeps a Buy rating on the shares, stating that ERAS-0015 PDAC data “continue to move in…
Erasca 31.429M share Spot Secondary priced at $17.50
The deal size was increased to $550M in common stock from $500M in common stock and priced at the offering price of $17.50 vs a close of $17.90. JPMorgan, Morgan…
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in Erasca, Inc. Lawsuit - ERAS
Important Information Regarding Section 20(a) Individual Liability Claims: Erasca's CEO and CFO Allegedly Certified Misleading Statements About ERAS-0015 While the Company Raised $258.8 Million From I...
Erasca price target raised to $18 from $16 at BofA
BofA analyst Alex Stranahan raised the firm’s price target on Erasca (ERAS) to $18 from $16 and keeps a Neutral rating on the shares. Erasca’s updated ERAS-0015 disclosure “modestly improves”…
Erasca Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...
Erasca $500M Spot Secondary being re-offered at $17.50
JPMorgan, Morgan Stanley, Jefferies and Evercore ISI are acting as joint book running managers for the offering.
Erasca announces $500M common stock offering
Erasca (ERAS) announced that it intends to offer and sell, subject to market and other conditions, $500M of shares of its common stock in a proposed underwritten public offering. All…
Erasca files automatic mixed securities shelf
16:18 EDT Erasca (ERAS) files automatic mixed securities shelf
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...
Erasca announces updated preliminary ERAS-0015 data
Erasca (ERAS) announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. The company also announced clinical development plans for th...
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100%
Erasca initiated with Early Stage Biotech at Goldman Sachs
Goldman Sachs initiated coverage of Erasca (ERAS) with an Early Stage Biotech rating. The company is developing assets in the pan-RAS and pan-KRAS space, which collectively target up to one-third…
ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigati...
ERAS Stockholders Have Rights - If you Lost Money Investing in Erasca, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 2, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securi...
ERASCA, INC. (ERAS) INVESTOR ALERT Investors With Large Losses in Erasca, Inc. Should Contact Bernstein Liebhard LLP to Discuss Their Rights
NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset
SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Investors in Erasca, Inc. (NASDAQ: ERAS) saw the price of their shares tank $9.25 (-48%) on April 28, 2026 after the company announced that it is facing a ...
Erasca upgraded to Neutral from Underperform at BofA
BofA upgraded Erasca (ERAS) to Neutral from Underperform with a price target of $16, up from $9. The firm says the investor debate is now shifting from whether ERAS-0015 works…
Erasca Transcript: Jefferies Global Healthcare Conference 2026
Two lead RAS-targeting agents are advancing in phase I trials, with ERAS-0015 showing strong response rates in NSCLC and promising early data in pancreatic and colorectal cancers. Safety and durability profiles are favorable, and key data updates are expected next year.
Erasca to Present at the Jefferies Global Healthcare Conference
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa...
Erasca Transcript: Bank of America Global Healthcare Conference 2026
ERAS-0015 shows strong efficacy and safety in key cancers, with expansion cohorts enrolling and combination studies underway. The company is advancing both pan-RAS and pan-KRAS programs, prioritizing combinations and capital efficiency to address high unmet needs in lung, pancreatic, and colorectal cancers.
Erasca price target lowered to $26 from $28 at Mizuho
Mizuho lowered the firm’s price target on Erasca (ERAS) to $26 from $28 and keeps an Outperform rating on the shares.
Erasca reports Q1 EPS (60c), consensus (23c)
“We continue to execute well across our RAS-targeting franchise, advancing ERAS-0015 clinical development ahead of schedule,” said Jonathan Lim, Erasca’s (ERAS) chairman, CEO, and co-founder. “The bes...
Erasca Reports First Quarter 2026 Business Updates and Financial Results
Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targ...